김현지 (인하대학교) | 한빛사논문 > 한빛사

한빛사논문

조회152

김현지Hyunji Kim

인하대학교

Adv. Funct. Mater., Volume35, Issue2 January 9, 2025 2412160 | https://doi.org/10.1002/adfm.202412160 Peptide Drones Facilitating the Transdermal Delivery of Antitumor Proteins for Melanoma Treatment

Hyunji Kim¹, Suin Kim¹, Guewha Lee², Ji-eun Kim³, Woo-jin Jeong^1,4

¹Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212 Republic of Korea
²Hu Evergreen Pharm, Incheon, 22204 Republic of Korea
³Department of Chemical and Biochemical Engineering, Dongguk University, 30 Pildong-ro 1-gil, Jung-gu, Seoul, 04620 Republic of Korea
⁴Department of Biological Engineering, Inha University, Incheon, 22212 Republic of Korea

H.K., S.I.K., and G.L. contributed equally to this work.
Corresponding Author: Woo-jin Jeong

Abstract

Topical treatment offers a viable alternative for melanoma patients incompatible with surgical interventions. Herein, the study develops a skin-penetrating peptide (SPP)-based peptide drone (PD) for the transdermal delivery of antitumor proteins. To achieve cost-effective therapeutics, Concanavalin A (ConA), which can be prepared through an extraction method, is loaded onto PDs. Compared with free proteins, ConA-PD complexes (CPCs) demonstrate significantly greater skin permeation. Moreover, the CPCs exhibit potent anticancer activity both in vitro and in vivo, which substantially surpass the efficacy of the Aldara (imiquimod) cream. The CPC-treated mouse skin remains clear, whereas Aldara cream induces side effects, including psoriasis-like skin inflammation. The antimetastatic activity of the PD is identified as another advantage of CPC. The use of ConA as an anticancer agent has been significantly limited due to its high hepatotoxicity; however, the transdermal delivery strategy minimizes its hepatic absorption and, in turn, results in negligible hepatotoxicity. These results demonstrate the potential of the CPC as a novel therapeutic agent or an adjunct to other modalities for melanoma treatment, overcoming the limitations of existing materials while exhibiting superior efficacy.

논문정보

형식Research article
게재일2025년 01월 (BRIC 등록일 2025-02-28)
연구진국내 연구진
분야 바이오·의료융합 > 바이오·의료융합 기타

댓글 작성 로그인

CV 열람하기

연락처 보기